Mark S. Kaminski
University of Michigan Medical Center
Ann Arbor
MI 48109-0936
USA
Name/email consistency: high
- 131I-tositumomab therapy as initial treatment for follicular lymphoma. Kaminski, M.S., Tuck, M., Estes, J., Kolstad, A., Ross, C.W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., Wahl, R.L. N. Engl. J. Med. (2005)
- Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Kaminski, M.S., Radford, J.A., Gregory, S.A., Leonard, J.P., Knox, S.J., Kroll, S., Wahl, R.L. J. Clin. Oncol. (2005)
- Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Kaminski, M.S., Zelenetz, A.D., Press, O.W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T.A., Stagg, R.J., Tidmarsh, G.F., Kroll, S., Wahl, R.L., Knox, S.J., Vose, J.M. J. Clin. Oncol. (2001)
- Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Kaminski, M.S., Estes, J., Zasadny, K.R., Francis, I.R., Ross, C.W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G., Wahl, R.L. Blood (2000)
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Kaminski, M.S., Zasadny, K.R., Francis, I.R., Fenner, M.C., Ross, C.W., Milik, A.W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S.D., Wahl, R.L. J. Clin. Oncol. (1996)